{"id":"NCT01772134","sponsor":"GlaxoSmithKline","briefTitle":"Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks","officialTitle":"A Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks With COPD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01-01","primaryCompletion":"2013-07-01","completion":"2013-07-22","firstPosted":"2013-01-21","resultsPosted":"2014-04-16","lastUpdate":"2018-01-29"},"enrollment":617,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"Umeclidinium bromide 62.5mcg","otherNames":[]},{"type":"DRUG","name":"Umeclidinium bromide 125mcg","otherNames":[]},{"type":"DRUG","name":"Fluticasone propionate 250mcg/Salmeterol 50mcg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Umeclidinium bromide 62.5 + Fluticasone propionate/Salmeterol","type":"EXPERIMENTAL"},{"label":"Umeclidinium bromide 125 + Fluticasone propionate/Salmeterol","type":"ACTIVE_COMPARATOR"},{"label":"Placebo + Fluticasone propionate/Salmeterol","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticanse propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to fluticanse propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticanse propionate/salmeterol (250/50mcg) twice-daily on lung function, COPD-related health status assessments and safety in COPD subjects.","primaryOutcome":{"measure":"Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85","timeFrame":"Baseline and Day 85","effectByArm":[{"arm":"Placebo QD + FSC 250/50 µg BID","deltaMin":-0.022,"sd":0.0146},{"arm":"UMEC 62.5 µg QD + FSC 250/50 µg BID","deltaMin":0.125,"sd":0.0142},{"arm":"UMEC 125 µg QD + FSC 250/50 µg BID","deltaMin":0.116,"sd":0.0144}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":16},"locations":{"siteCount":73,"countries":["United States","Canada","Germany","South Korea"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":205},"commonTop":["Headache","Nasopharyngitis","Cough"]}}